Robert J. Schotzinger

Dr. Schotzinger is a veteran of the pharmaceutical industry with over 25 years of research, development, financing and management experience. Most recently, Dr. Schotzinger was co-founder and CEO of Viamet Pharmaceuticals where he raised significant equity capital and moved Viamet Pharmaceuticals from a seed-stage company to a successful clinical-stage company. Viamet Pharmaceuticals was acquired by NovaQuest Capital Management in 2018. Prior to founding Viamet Pharmaceuticals, Dr. Schotzinger was President and CEO of BioStratum, where he was responsible for progressing the company’s lead drug candidate from Phase 1 to Phase 3. Dr. Schotzinger began his pharmaceutical career at Abbott Laboratories where he held positions of increasing responsibility, including Director of International Medical Affairs and Vice President of Drug Development.